A detailed mechanistic analysis of the contribution of ZNF217 to therapeutic resistance combined with pre-clinical modeling will inform the design of the best treatment plan to kill these cells, thereby reducing mortality in breast cancer patients with aggressive disease. Here, ZNF217 is linked to breast carcinoma.